Volume 154, Issue 1, Pages (July 2019)

Slides:

Advertisements

Similar presentations

Regional variation in histopathology-specific incidence of invasive cervical cancer among Peruvian women Christine M. Pierce Campbell, Maria P. Curado,

Advertisements

Nicoletta Colombo, Martin Gore

Volume 144, Issue 1, Pages (January 2017)

Comparison of the efficacy and safety of single-agent and doublet chemotherapy in advanced non-small cell lung cancer in the elderly: A meta-analysis

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions Chelsea.

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey Lazzaro Repetto Critical.

Critical Reviews in Oncology / Hematology

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Volume 150, Issue 1, Pages (July 2018)

Volume 148, Issue 1, Pages (January 2018)

Are patients willing to travel for better ovarian cancer care?

Volume 148, Issue 1, Pages (January 2018)

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 146, Issue 3, Pages (September 2017)

Volume 58, Issue 5, Pages (November 2010)

Volume 149, Issue 2, Pages (May 2018)

Volume 145, Issue 2, Pages (May 2017)

Volume 138, Issue 1, Pages (July 2015)

Vulvar intraepithelial neoplasia: Risk factors for recurrence

Corrigendum to “MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer” [Gynecologic Oncology 110: 13–21, 2008] Douglas.

The efficacy of mTORC1/2 inhibition on ovarian cancer stem cells

Volume 152, Issue 1, Pages (January 2019)

Volume 141, Issue 2, Pages (May 2016)

Volume 51, Issue 5, Pages (May 2007)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Volume 151, Issue 1, Pages (October 2018)

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 148, Issue 1, Pages (January 2018)

Volume 136, Issue 2, Pages (February 2015)

Supportive care plans: Linking patient-reported outcomes to evidence-based supportive care across the cancer continuum E.E. Stevens, J.N. Bottsford-Miller,

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 146, Issue 1, Pages (July 2017)

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 147, Issue 2, Pages (November 2017)

Volume 152, Issue 1, Pages (January 2019)

Roy Hertz, M.D. (1909–2002): The cure of choriocarcinoma and its impact on the development of chemotherapy for cancer Jonathan P Yarris, B.S., Alan J.

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

The origins of multidisciplinary cancer care

Adherence to hematologic hold parameters in dose-dense chemotherapy for ovarian malignancies: A survey of the National Comprehensive Cancer Network (NCCN)

Comparing the health and economic impacts of cervical cancer screening strategies using the Cancer Risk Management Model (CRMM) C. Popadiuk, A.J. Coldman,

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Survivors' acceptance of treatment side effects evolves as goals of care change over the cancer continuum A. Ellis, M.K. Frey, L.M. Koontz, S. Shyne,

Volume 150, Issue 1, Pages (July 2018)

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Volume 130, Issue 3, Pages (September 2013)

The complex interaction of cancer surgery, complications, and patient-reported outcomes: A single score is not enough K.M. Doll, E.L. Barber, J.T. Bensen,

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Volume 147, Issue 3, Pages (December 2017)

Volume 152, Issue 1, Pages (January 2019)

Histologic analysis of specimens from laparoscopic endometrioma excision performed by different surgeons: does the surgeon matter? Ludovico Muzii, M.D.,

Volume 152, Issue 1, Pages (January 2019)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 147, Issue 3, Pages (December 2017)

High-risk cancer, unequal care: Disparities in the complete surgical staging of high- grade endometrial cancer in the Southeastern United States J.R.

Mechanical bowel preparation before gynecologic laparoscopy: a randomized, single- blind, controlled trial Ludovico Muzii, M.D., Filippo Bellati, M.D.,

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Ludovico Muzii, M. D. , Filippo Bellati, M. D. , Natalina Manci, M. D

Volume 115, Issue 1, Pages (October 2009)

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 154, Issue 1, Pages 138-143 (July 2019) Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients? Federica Tomao, Lucia Musacchio, Federica Di Mauro, Serena Maria Boccia, Violante Di Donato, Antonella Giancotti, Giorgia Perniola, Innocenza Palaia, Ludovico Muzii, Pierluigi Benedetti Panici Gynecologic Oncology Volume 154, Issue 1, Pages 138-143 (July 2019) DOI: 10.1016/j.ygyno.2019.04.009 Copyright © 2019 The Authors Terms and Conditions

Fig. 1 Rates of anemia and neutropenia per cycle among OC patients underwent chemotherapy, according to BRCA mutational status. Gynecologic Oncology 2019 154, 138-143DOI: (10.1016/j.ygyno.2019.04.009) Copyright © 2019 The Authors Terms and Conditions

Fig. 2 Rates of anemia and neutropenia in NACT patients per cycle, according to BRCA mutational status. Gynecologic Oncology 2019 154, 138-143DOI: (10.1016/j.ygyno.2019.04.009) Copyright © 2019 The Authors Terms and Conditions